India Frets FDI In Local Pharmas Could Weaken Drug Access At Home
This article was originally published in PharmAsia News
Indian authorities are concerned that direct investments in local drug makers by foreign companies could lead the India firms to shift focus away from their own market
You may also be interested in...
National export restrictions on medicines have been slammed by the international off-patent pharmaceutical industry as being “counter-productive” during the coronavirus crisis. The IGBA is instead urging international co-operation and transparency, pointing to a positive example of supply-chain connectivity in the Asia-Pacific region.
Claims circulated on social media that its Cebion supplement could prevent coronavirus has led Italy's Dompé to take legal action.
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.